Prevalence and characteristics of bone disease in cirrhotic patients.
25-OH vitamin D
chronic liver disease
osteopenia
osteoporosis
survival
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
09
04
2020
accepted:
28
04
2020
entrez:
11
8
2022
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
Chronic liver disease is a risk factor for osteoporosis, osteopenia and bone fractures. In this study, prevalence and risk factors of osteoporosis and vitamin D deficiency and also their effects on survival were investigated in 218 patients with chronic liver disease. Prevalence of osteoporosis and vitamin D levels was calculated. Risk factors for osteoporosis (gender, age, body mass index, etiology), serum bilirubin, albumin, 25-hydroxy (OH) vitamin D, parathyroid hormone levels, bone mineral density (BMD) with DEXA, bone formation (osteocalcin) and bone resorption (type 1 collagen) levels, Model for End-Stage Liver Disease (MELD) Na and Child-Pugh (CP) score were recorded. The effects of vitamin D levels and BMD on survival were evaluated. One hundred forty-seven (67.4%) patients were female (mean age, 50.4±11.7). Patients were Child A by 40.8%, Child B by 47.1%, and Child C by 12.1%. Mean MELD Na score was 8.4±2.8. Data of the BMD were established in 218 patients and 25-OH D levels in 122 patients. Mean serum 25-OH D level was 14.26±9.44 ng/mL. Osteoporosis was identified in 42 (19.3%) and osteopenia in 115 (52.8%) patients, according to BMD. Osteocalcin levels and collagen type 1 levels were high in 25.6% and 12.5% of patients, respectively. No statistically difference was found, including gender (p=0.69), age (p=0.38), etiology (p=0.16), BMI (p=0.32), CP score (p=0.42), MELD (0.14), albumin (p=0.11), total bilirubin (p=0.99), Ca (0.67), PTH (0.88), osteocalcin (0.92), collagen type 1(p=0.25) between osteoporotic and non-osteoporotic patients. Patients were followed-up for a median of 30.07±11.83 months after BMD measurement. Fifty-four (24.8%) patients died during the follow-up period, none of them are related to bone fracture. There was no statistically difference on survival between osteoporosis group (32.2±2.3 months) and non-osteoporosis group (37.2±1.7 months; p=0.26) or when patients with 25-OH D In conclusion, the prevalence of bone disease was found to be higher in cirrhotic patients. Although osteoporosis and vitamin D deficiency were found to decrease survival, this effect was not statistically significant. We suggest designing multi-institutional and/or multinational studies with larger and more heterogenous patient groups would enable better testing of this phenomenon.
Sections du résumé
Background and Aim
UNASSIGNED
Chronic liver disease is a risk factor for osteoporosis, osteopenia and bone fractures. In this study, prevalence and risk factors of osteoporosis and vitamin D deficiency and also their effects on survival were investigated in 218 patients with chronic liver disease.
Materials and Methods
UNASSIGNED
Prevalence of osteoporosis and vitamin D levels was calculated. Risk factors for osteoporosis (gender, age, body mass index, etiology), serum bilirubin, albumin, 25-hydroxy (OH) vitamin D, parathyroid hormone levels, bone mineral density (BMD) with DEXA, bone formation (osteocalcin) and bone resorption (type 1 collagen) levels, Model for End-Stage Liver Disease (MELD) Na and Child-Pugh (CP) score were recorded. The effects of vitamin D levels and BMD on survival were evaluated.
Results
UNASSIGNED
One hundred forty-seven (67.4%) patients were female (mean age, 50.4±11.7). Patients were Child A by 40.8%, Child B by 47.1%, and Child C by 12.1%. Mean MELD Na score was 8.4±2.8. Data of the BMD were established in 218 patients and 25-OH D levels in 122 patients. Mean serum 25-OH D level was 14.26±9.44 ng/mL. Osteoporosis was identified in 42 (19.3%) and osteopenia in 115 (52.8%) patients, according to BMD. Osteocalcin levels and collagen type 1 levels were high in 25.6% and 12.5% of patients, respectively. No statistically difference was found, including gender (p=0.69), age (p=0.38), etiology (p=0.16), BMI (p=0.32), CP score (p=0.42), MELD (0.14), albumin (p=0.11), total bilirubin (p=0.99), Ca (0.67), PTH (0.88), osteocalcin (0.92), collagen type 1(p=0.25) between osteoporotic and non-osteoporotic patients. Patients were followed-up for a median of 30.07±11.83 months after BMD measurement. Fifty-four (24.8%) patients died during the follow-up period, none of them are related to bone fracture. There was no statistically difference on survival between osteoporosis group (32.2±2.3 months) and non-osteoporosis group (37.2±1.7 months; p=0.26) or when patients with 25-OH D
Conclusion
UNASSIGNED
In conclusion, the prevalence of bone disease was found to be higher in cirrhotic patients. Although osteoporosis and vitamin D deficiency were found to decrease survival, this effect was not statistically significant. We suggest designing multi-institutional and/or multinational studies with larger and more heterogenous patient groups would enable better testing of this phenomenon.
Identifiants
pubmed: 35949442
doi: 10.14744/hf.2020.2020.0007
pii: hf-1-048
pmc: PMC9349342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-52Informations de copyright
© Copyright 2020 by Hepatology Forum.
Déclaration de conflit d'intérêts
The authors do not have any conflict of interest.
Références
Hepatology. 2007 Oct;46(4):1271-8
pubmed: 17886334
FASEB J. 2001 Dec;15(14):2579-85
pubmed: 11726533
Eur J Gastroenterol Hepatol. 2000 Aug;12(8):931-5
pubmed: 10958221
Nutr Clin Pract. 2013 Feb;28(1):52-64
pubmed: 23263929
J Mol Cell Cardiol. 2006 Aug;41(2):350-9
pubmed: 16815434
Liver Int. 2007 May;27(4):492-7
pubmed: 17403189
J Immunol. 2007 Aug 1;179(3):1634-47
pubmed: 17641030
Liver Transpl. 2013 Jun;19(6):627-33
pubmed: 23495130
Clin Transplant. 2009 Nov-Dec;23(6):861-5
pubmed: 19453643
Nat Rev Gastroenterol Hepatol. 2009 Nov;6(11):660-70
pubmed: 19881518
Clin Cases Miner Bone Metab. 2014 Sep;11(3):185-91
pubmed: 25568651
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):355-60
pubmed: 15225800
N Engl J Med. 2011 Apr 14;364(15):1385-7
pubmed: 21428761
Am J Transplant. 2007 Jul;7(7):1763-9
pubmed: 17511759
Rev Esp Enferm Dig. 2013 Nov-Dec;105(10):609-21
pubmed: 24641458
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
World J Gastroenterol. 2010 Apr 7;16(13):1639-43
pubmed: 20355242
Dig Dis Sci. 2010 Sep;55(9):2624-8
pubmed: 19960254
Clin Transplant. 2014 May;28(5):579-84
pubmed: 24628047
Biomed Res Int. 2016;2016:1423462
pubmed: 27840821
Ann Pharmacother. 1999 Feb;33(2):233-5
pubmed: 10084420
World J Hepatol. 2011 Dec 27;3(12):300-7
pubmed: 22216370
World J Gastroenterol. 2005 Mar 28;11(12):1843-7
pubmed: 15793878
Curr Drug Targets. 2011 Jan;12(1):54-60
pubmed: 20795937
Liver Transpl. 2006 Sep;12(9):1390-402
pubmed: 16933236
Osteoporos Int. 2000;11(5):417-24
pubmed: 10912844
PLoS One. 2012;7(2):e27144
pubmed: 22359532
Transplant Proc. 2012 Jul-Aug;44(6):1496-8
pubmed: 22841194
Annu Rev Pharmacol Toxicol. 2011;51:311-36
pubmed: 20936945
J Gastroenterol Hepatol. 2011 Sep;26(9):1402-10
pubmed: 21501225